Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, April 28, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises MaravaiLifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ: MRVI) investors of a class action representing investors that bought securities between August 7, 2024 and February 24, 2025, inclusive (the "Class Period"). Acadia Healthcare investors have until May 5, 2025to file a lead plaintiff motion.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
The Maravai class action lawsuit alleges that, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) Maravai lacked adequate internal controls over financial reporting, specifically concerning revenue recognition; (ii) as a result, Maravai improperly recognized revenue for certain transactions during fiscal year 2024; and (iii) Maravai’s goodwill was overstated.
The lawsuit further claims that, on February 25, 2025, Maravai announced it was postponing its fiscal 2024 earnings release and delaying the filing of its annual report. The company disclosed that it needed additional time to complete its year-end financial close, primarily due to: (1) an assessment of a potential non-cash impairment charge related to goodwill from its prior acquisition of Alphazyme LLC; (2) the discovery of an error during the close process concerning revenue recognition, where approximately $3.9 million in revenue was incorrectly recorded in the final week of the second quarter of 2024 upon shipment rather than in the first week of the third quarter of 2024 upon receipt by the customer; and (3) an evaluation of the effectiveness of its disclosure controls, internal controls over financial reporting as of December 31, 2024, and any necessary remediation, including addressing a material weakness identified in its revenue recognition controls. Following this announcement, Maravai’s stock price declined by nearly 22%, according to the complaint.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com
Attorney Advertising
Maravai LifeSciences Holdings, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. May 5, 2025 Deadline to file Lead Plaintiff Motion.
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...